Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 325,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,490.3 pence per share.
- Treasury Shares Held: 191,941,678 shares (post-transaction).
- Shares in Issue: 5,794,087,360 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on September 12, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 17, 2006. The acquired shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the repurchase (325,000 shares at 1,490.3 pence) against cash flow statements in the most recent full financial report.
- Confirm the updated total share count and Treasury holdings in subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.